NCT04499352WithdrawnPhase 2
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Boehringer Ingelheim
- Locations
- 1
- Primary Endpoint
- Objective response (OR)
Study Overview
Brief Summary
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed and dated written Informed Consent Form (ICF) in accordance with ICH-GCP and local legislation prior to admission to the trial.
- •Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
- •Patients must have histologically or cytologically documented surgically unresectable locally-advanced or metastatic Squamous cell carcinoma of the anal canal (SCCA).
- •Patients with loco-regional anal cancer as initial diagnosis must have unresectable progressive locally advanced or metastatic SCCA after failure of at least one line (but not more than two lines) of previous systemic treatment unless ineligible for or intolerant to this systemic therapy.
- •Patients with metastatic anal cancer as initial diagnosis (no prior treatment for loco-regional cancer) must have failed one line of previous systemic treatment (chemotherapy ± radiotherapy) for the metastatic anal cancer unless ineligible for or intolerant to this systemic treatment. (Patients with metastatic anal cancer as initial diagnosis who have received two or more lines of systemic treatment for the metastatic anal cancer are not eligible for the study.)
- •All patients must have at least one measurable lesion according to RECIST v1.1 criteria.
- •Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 1
- •All patients must be willing to undergo blood testing for human immunodeficiency virus (HIV) presence in the blood if not tested within the past 6 months prior to signature of ICF for this trial.
- •For patients confirmed as HIV positive, all of the following (a-d) applies:
- •CD4+ count ≥ 250 cells/μL
- •Undetectable viral load (local lab assessment)
- •Must be currently receiving Highly Active Antiretroviral Therapy
- •A HIV/Infectious Diseases specialist must be consulted or patient must be under the care of the HIV/Infectious Diseases specialist
- •Patients must be willing to allow programmed cell death ligand 1 (PD-L1) status assessment by one of following options.
- •Preference is given to fresh tumour biopsy sample collection at baseline before receiving first trial medication. In case a fresh tumour biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), archival tissue will be requested. If neither is available any previous historical information regarding PD-L1 status should be collected via eCRF. Exceptions may be considered after consultation with and approval by the Sponsor.
- •Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, for the entire duration of the trial treatment intake and for 6 months after the end of the trial treatment. A list of contraception methods meeting these criteria is provided in the patient information.
Exclusion Criteria
- •Current or prior treatment with any systemic anti-cancer therapy or any investigational product (or device) either within 28 days or less than 5 half-lives (whichever is shorter) before start of trial treatment.
- •Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
- •Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > New York Heart Association (NYHA) II).
- •Uncontrolled hypertension is defined as: blood pressure in rested and relaxed condition ≥ 140 mmHg, systolic or ≥ 90 mmHg diastolic (with or without medication)
- •Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
- •History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
- •Patients who require full-dose anticoagulation (according to local guidelines). No Vitamin K antagonist and other anticoagulation allowed; Low-Molecular-Weight-Heparin (LMWH) and acetylsalicylic acid (ASA) allowed only for prevention not for curative treatment.
- •Prior treatment with anti-PD-1, anti-PD-L1, or anti CTLA-4 treatment
- •Prior treatment with any antiangiogenic agent (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc.) Further exclusion criteria apply.
Arms & Interventions
treatment arm A
Experimental
Intervention: BI 754091 (Drug)
treatment arm B
Experimental
Intervention: BI 754091 (Drug)
treatment arm B
Experimental
Intervention: BI 836880 (Drug)
Outcomes
Primary Outcomes
Objective response (OR)
Time Frame: up to 3 years
Secondary Outcomes
- Duration of objective response (DoR)(up to 3 years)
- Overall survival (OS)(up to 3 years)
- Adverse events (AEs)(up to 3 years)
- Drug related AEs leading to dose reduction of BI 836880 and/or discontinuation of study treatment (i.e. both trial drugs)(up to 3 years)
- Disease control (DC)(up to 3 years)
- Drug related AEs from the time of treatment initiation until the end of the Residual Effect Period (REP)(up to 3 years)
- Progression-free survival (PFS)(up to 3 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid TumoursSolid Tumor, AdultNCT03990233OSE Immunotherapeutics100
Completed
Early Phase 1
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of CancerNeoplasmsNCT03433898Boehringer Ingelheim146
Completed
Phase 2
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial CancerNeoplasmsNCT01023958Boehringer Ingelheim50
Completed
Phase 1
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT06055075Hoffmann-La Roche19
Completed
Phase 2
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC PatientsCarcinoma, Non-Small-Cell LungNCT00730925Boehringer Ingelheim41